Cargando…

Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients

BACKGROUND: Tenofovir (TDF) and ritonavir-boosted lopinavir (LPV/r) were not introduced to China as second-line medications until 2009. The efficacy and safety of TDF/3TC/LPV/r based second-line regimen have not been evaluated in Chinese HIV patients who failed first-line regimens. METHODS: This was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Yang, Li, Yijia, Xie, Jing, Qiu, Zhifeng, Li, Yanling, Song, Xiaojing, Zhu, Ting, Li, Taisheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379083/ https://www.ncbi.nlm.nih.gov/pubmed/25821963 http://dx.doi.org/10.1371/journal.pone.0120705

Ejemplares similares

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
por: Zhao, Ying, et al.
Publicado: (2021)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
por: Keene, Claire M, et al.
Publicado: (2023)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
por: Park, Chan Ho, et al.
Publicado: (2016)

A prospective study to estimate the incidence and pattern of adverse drug reactions to first-line antiretroviral therapy (tenofovir, efavirenz, and lamivudine)
por: Singh, Boby, et al.
Publicado: (2023)

Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects
por: Li, Yijia, et al.
Publicado: (2016)

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study
por: Cao, Ying, et al.
Publicado: (2013)

Risk factors and longitudinal changes of dyslipidemia among Chinese people living with HIV receiving antiretroviral therapy
por: Li, Xiuxia, et al.
Publicado: (2023)

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1
Publicado: (2019)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
por: Hakim, James G, et al.
Publicado: (2018)

Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti
por: Pierre, Samuel, et al.
Publicado: (2021)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study
por: Xie, Jing, et al.
Publicado: (2016)

Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data
por: Rodriguez, Allan E, et al.
Publicado: (2010)

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine
por: Haskelberg, Hila, et al.
Publicado: (2014)

Laboratory Based Surveillance of HIV-1 Acquired Drug Resistance in Cameroon: Implications for Use of Tenofovir-Lamivudine-Dolutegravir (TLD) as Second- or Third-Line Regimens
por: Fokam, Joseph, et al.
Publicado: (2023)

Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China
por: Guo, Peng-Le, et al.
Publicado: (2021)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients
por: Minzi, OM, et al.
Publicado: (2011)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial
por: Ulbricht, K.U, et al.
Publicado: (2011)

Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment
por: Steegen, Kim, et al.
Publicado: (2022)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation Cohort
por: Li, Taisheng, et al.
Publicado: (2008)

Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)

A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study
por: Yue, Yongsong, et al.
Publicado: (2017)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Tenofovir as Rescue Therapy Following Clinical Failure to Lamivudine in Severe Acute Hepatitis B
por: Gerada, Jurgen, et al.
Publicado: (2013)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
por: Rodríguez, Manuel, et al.
Publicado: (2017)

LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2018)

Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients
por: Patel, Dishank, et al.
Publicado: (2013)

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease
por: Guo, Fuping, et al.
Publicado: (2017)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2eidvnqfdvqbnc84er6gg22t55